Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 8/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.38 |
| ▸ | HTR2C | P28335 | 2/20 | 0.38 |
| ▸ | HTR2B | P41595 | 2/20 | 0.38 |
| ▸ | KMO | O15229 | 2/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23909099 | 0.94 | CNR2 (0.38) | CNR2SCN9AHTR2CHTR2BKMO | |
| SCHEMBL23908770 | 0.86 | HTR2C (0.41) | CNR2SCN9AHTR2CHTR2BKMO | |
| SCHEMBL20201737 | 0.81 | CNR2 (0.40) | CNR2SCN9AKMOFFAR4 | |
| SCHEMBL16135136 | 0.81 | CYP3A4 (0.40) | HTR2CHTR2BNOS3NOS1NOS2 | |
| SCHEMBL9873759 | 0.81 | FFAR4 (0.44) | SCN9AHTR2CHTR2BFFAR4 | |
| SCHEMBL10003961 | 0.81 | CNR2 (0.38) | CNR2SCN9AHTR2CHTR2BKMO | |
| SCHEMBL24777832 | 0.81 | SCN9A (0.49) | SCN9AFFAR4 | |
| SCHEMBL5241392 | 0.81 | CNR2 (0.38) | CNR2SCN9AHTR2CHTR2BKMO | |
| SCHEMBL20201700 | 0.78 | ALDH1A1 (0.42) | CNR2HTR2CHTR2BKMO | |
| SCHEMBL13254972 | 0.78 | KDM4E (0.46) | HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3649119-B1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GALAPAGOS NV (BE) | 2021-11-03 | — | — | EP | disclosed |
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GILEAD SCIENCES, INC. | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | S1PR1, S1PR3, S1PR2 | CNR2 17/4885SCN9A 3355/4885HTR2C 1276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.